Jonathan Zalevsky, Chief R&D Officer at NEKTAR THERAPEUTICS (NKTR), sold 21,120 shares at $4.76 ($101K) on 2022-08-16, disclosed to the SEC on 2022-08-17.
Open-market sale of $101k NKTR by Chief R&D Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.76 | 10,560 | $50K | 50.0% |
| 2 | $4.76 | 10,560 | $50K | 50.0% |
| Total | $4.76 avg | 21,120 | $101K | 100% |
| Filing → |
| NKTR | SELL | 2026-06-17 | $336K | — | Filing → |
| NKTR | SELL | 2026-05-21 | $13K | — | Filing → |
| NKTR | SELL | 2026-02-20 | $13K | — | Filing → |